Publications by authors named "M F Neurath"
Background: Data regarding multiple switches including reverse switching between infliximab and its biosimilars are scarce in the field of inflammatory bowel diseases (IBD).
Objectives: We investigated the clinical effectiveness as primary outcome measure after repeated switches. Secondary endpoints included C-reactive protein (CRP) levels, immunogenicity (trough levels (TL); anti-drug antibodies (ADA), safety and drug persistence.
Article Synopsis
- A 70-year-old Caucasian man with advanced colorectal cancer developed a complete obstruction in his small intestine six months after getting a diverting ileostomy.
- He was not eligible for surgery due to previous tumor perforation, so doctors used an endoscopic ultrasound-guided technique to create a new passage in the intestines.
- The procedure was successful, allowing the patient to resume oral nutrition the following day and leave the hospital in better health after three days.
Background: Paraduodenal pancreatitis (PP) is an inflammation involving the groove zone, delimited by the duodenum lumen, bile duct, and the head of the pancreas. This area may also be involved during acute pancreatitis (AP). The differential diagnosis is clinically relevant, since PP generally persists, whereas AP resolves.
View Article and Find Full Text PDFArticle Synopsis
- Physical training is known to lower cancer risk, and it’s suggested that myokines released by skeletal muscle have an anti-tumor effect, but more research is needed, particularly in breast cancer patients.
- A study involving 12 weeks of resistance training with whole-body electromyostimulation (WB-EMS) showed improvements in physical performance and muscle mass in breast cancer patients, along with their blood serum inhibiting cancer cell growth in lab tests.
- The research highlights that myokines, like CXCL1, IL10, and CCL4, can enhance the death of cancer cells, indicating the potential for physical exercise to be a supportive therapy in breast
Molecular Imaging: The New Frontier for Endoscopic Diagnosis and Personalization in Inflammatory Bowel Disease.
Gastrointest Endosc Clin N Am
January 2025
Molecular endoscopy in inflammatory bowel disease (IBD) has made the translation from preclinical studies to clinical trials. The so far performed in vivo studies, using fluorescent antibodies, have addressed areas of heightened clinical interest with unmet needs. These include the distribution of targeted therapies within the mucosa, which could elucidate the most fitting dosing for the individual patient, the mode of action of currently used treatments, and subsequently also the prediction of therapeutic response.
View Article and Find Full Text PDF